PDR001 in Combination With Platinum-doublet Chemotherapy and Other Immunology Agents in PD-L1 Unselected, Metastatic NSCLC Patients
Stopped early · Phase 1
Conditions studied: Non-small Cell Lung Cancer
In brief
The primary purpose of this study is to establish the maximum tolerated dose (MTD) and/or recommended dose for expansion (RDE) of PDR001 when administered in combination with platinum-doublet chemotherapy and other immunooncology agent(s) in treatment naive patients with PD-L1 unselected, advanced NSCLC, and to estimate the preliminary anti-tumor activity in this patient population.
Key facts
- Study ID
- NCT03064854
- Run by
- Novartis Pharmaceuticals
- People needed
- 111
- Starts
- 2017-05-24
- Expected to finish
- 2021-07-28
- Last updated by the study team
- 2022-08-15
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Highlands Oncology Group — Fayetteville, Arkansas, United States
- UCLA Santa Monica Hematology / Oncology SC-2 — Santa Monica, California, United States
- Stanford Cancer Center SC — Stanford, California, United States
- Henry Ford Health System SC — Detroit, Michigan, United States
- Washington University School of Medicine SC — St Louis, Missouri, United States
- Novartis Investigative Site — Leuven, Belgium
- Novartis Investigative Site — Roeselare, Belgium
- Novartis Investigative Site — Toronto, Ontario, Canada
- Novartis Investigative Site — Prague, Czechia
- Novartis Investigative Site — Lyon, France
- Novartis Investigative Site — Marseille, France
- Novartis Investigative Site — Cologne, Germany
- Novartis Investigative Site — Göttingen, Germany
- Novartis Investigative Site — Pokfulam, Hong Kong, Hong Kong
- Novartis Investigative Site — Meldola, FC, Italy
- Novartis Investigative Site — Rozzano, MI, Italy
- Novartis Investigative Site — Aviano, PN, Italy
- Novartis Investigative Site — Amsterdam, Netherlands
- Novartis Investigative Site — Singapore, Singapore
- Novartis Investigative Site — Seoul, South Korea
- Novartis Investigative Site — Barcelona, Catalonia, Spain
- Novartis Investigative Site — Madrid, Spain
- Novartis Investigative Site — Madrid, Spain
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.